Podcast Episode 21: Clinical Accuracy in CGM and Why It Matters
Sponsored by 
Guest Speakers: Dr. Jessica Castle and Dr. Stayce Beck
Real-time real talk is intended for healthcare professionals in the US.
In this episode of Real Time Real-Talk, host Cher Pastore is joined by Dr. Jessica Castle and Dr. Stayce Beck to discuss the process behind the formulation and execution of continuous glucose monitoring (CGM) accuracy trials.
The trio discuss the influence of rigorous trial design and transparency on the accuracy and reliability of CGM devices, particularly those developed by Dexcom. They highlight the importance of CGM research's credibility, strategies to minimize bias, and the essential role that regulatory bodies play in ensuring quality health research. The discussion also covers the dynamics of conflicts of interest, patient and healthcare provider education, and the significance of detailed metrics for evaluating CGM performance.
Our expert panel also take us behind the scenes to reveal the meticulous work involved in creating and executing CGM studies that encompass different populations and conditions. The episode includes discussions around key performance metrics in a CGM accuracy study, understanding why blood glucose monitor and CGM readings might not match and the explanation of relative difference and CGM accuracy.
Finally, listen as they walk through the process of bringing transparency to CGM data analysis, alongside discussing the potential challenges and future of CGM device application in pediatric hospital discharge programs, probing into the potential barriers and challenges faced by healthcare providers and patients.
The conversation highlights the comprehensive journey towards ensuring users can trust their CGM readings, right from day one to real-world applications.
Presenters
Jessica Castle, MD
Dr Castle is board-certified adult endocrinologist with 15 years of experience in clinical trials in the field of diabetes. She served as the Associate Director of the Harold Schnitzer Diabetes Health Center, where they provided care to 5,900 patients living with diabetes. She is also board-certified in internal medicine. Her clinical trial experience includes obtaining 11 investigational device exemptions from the FDA for automated insulin delivery and decision support studies. She has been on numerous data safety monitoring boards, including boards overseeing multiple large multi-center automated insulin delivery trials and for trials based both in the US and in Europe.